News | News By Subject | News by Disease News By Date | Search News

Pulmonary Embolism News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation     6/26/2014
Boehringer Ingelheim Corporation's Pradaxa® Wins EU Approval To Treat Deep Vein Thrombosis And Pulmonary Embolisms     6/6/2014
Bayer HealthCare (BAY) Says Lung Drug Shows Promise in Prolonged Trial     5/22/2013
Bayer AG (BAY.F), Johnson & Johnson (JNJ)'s Xarelto Gets FDA Priority Review     7/10/2012
Bayer AG (BAY.F) Seeks EU Approval of Xarelto for Pulmonary Embolism     4/13/2012
FDA Issues Import Alerts for 22 Chinese Heparin Suppliers     2/24/2012
Positive Results of Study Evaluating Accuracy and Safety of Agenix Limited's ThromboView(R) Diagnostic Featured in Leading US Peer Review Medical Journal     7/8/2011
Encysive Pharmaceuticals (ENCY) Shares Dive After New Delay On Lung Drug     7/25/2006
FDA Grants Class 1 Review To Encysive Pharmaceuticals (ENCY)' Complete Response To Thelin(TM) New Drug Application; Shares Leap     6/16/2006
FDA Grants Fast Track Designation To Nektar Therapeutics (NKTR)'s Amphotericin B Inhalation Powder (ABIP) For Prevention Of Pulmonary Fungal Infections In At-Risk Patients     5/22/2006
Debiopharm S.A. And Dyax Corp. (DYAX) Restructure Development Agreement For DEPELESTAT In Pulmonary Disorders     12/20/2005
Savient Pharmaceuticals, Inc. (SVNT) To Sell Global Biologics Manufacturing Business For $80 Million To Ferring Holding SA; Major Milestone Achieved In Savient's New Strategic Direction     3/23/2005
Glenmark Pharmaceuticals And Forest Laboratories, Inc. (FRX) Announce Collaboration Agreement On PDE4 Inhibitor For Asthma And COPD     9/23/2004

News from Around the Web
No News Posted on that date

Press Releases
Bayer (BAY) Release: New Study Finds Thousands Of Pulmonary Embolism Patients May Later Develop A Life-Threatening Form Of Pulmonary Hypertension     4/7/2016
Boehringer Ingelheim Launches Observational Study On Management Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) With Pradaxa (dabigatran etexilate mesylate)     3/23/2016
Inari Medical Announces IDE Approval To Study The FlowTriever System For The Treatment Of Pulmonary Embolism     3/8/2016
Bristol-Myers Squibb (BMY) Release: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death And Major Bleeding In Deep Vein Thrombosis And Pulmonary Embolism Patients Treated Witheliquis (Apixaban) Or Conventional Therapy     12/11/2015
Boehringer Ingelheim Release: FDA Approves Pradaxa (dabigatran etexilate mesylate) For Prophylaxis Of Deep Venous Thrombosis (DVT) And Pulmonary Embolism (PE) After Hip Replacement Surgery     11/23/2015
Daiichi Sankyo Release: NICE Recommends Once-daily LIXIANA (edoxaban) For The Treatment And Prevention Of Recurrent Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) In Adults     7/13/2015
Bayer HealthCare (BAY) Release: New Data Show Need For Improved Monitoring For Pulmonary Hypertension Following Pulmonary Embolism     5/20/2015
FDA Files Supplemental New Drug Application For Boehringer Ingelheim's Pradaxa (dabigatran etexilate mesylate) For The Prophylaxis Of Deep Venous Thrombosis And Pulmonary Embolism After Hip Replacement Surgery     4/6/2015
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE     11/26/2014
Bristol-Myers Squibb Company (BMY) Release: ELIQUIS Approved For Treatment Of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) And Prevention Of Recurrent DVT And PE     11/26/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Phase III Study Of Dabigatran Etexilate Mesylate Met Primary Endpoint For Six-Month Treatment Of Deep Vein Thrombosis (DVT) And/Or Pulmonary Embolism (PE)     12/17/2013
Boehringer Ingelheim Corporation Release: New Findings From Two Studies Support Substantial Benefit of Pradaxa® for Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism     2/21/2013
Daiichi Sankyo, Inc. (4568.t) Completes Enrollment in Hokusai - VTE, Investigating Once-Daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE     10/25/2012
Pfizer Inc. (PFE) Release: New Data Presented On Phase 3 Trial of ELIQUIS® (apixaban) In the Prevention Of Venous Thromboembolism in Patients With Acute Medical Illness     11/14/2011
Ablynx Selects A Novel Pre-Clinical Development Candidate For Administration Via Pulmonary Delivery     3/26/2010